379270-37-8
379270-37-8 structure
- Name: Tenofovir alafenamide
- Chemical Name: propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
- CAS Number: 379270-37-8
- Molecular Formula: C21H29N6O5P
- Molecular Weight: 476.466
- Catalog: API Inhibitor
- Create Date: 2018-02-06 08:00:00
- Modify Date: 2026-07-01 16:46:59
-
Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
| Name | propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate |
|---|---|
| Synonyms |
Tenofovir Alafenamide N-2
Alafenamide Isopropyl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)(phenoxy)phosphoryl]-L-alaninate Tenofovir Alafenamide (GS-7340) L- Alanine,N-[(S)-[[(1R)-2-(6 (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl) Tenofovir Alafenamide Impurity GS-7340/GS7340 GS-7340 L-Alanine, N-[(S)-[(1S)-[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester Tenofovir alafenamide, 10 mM in DMSO Tenofovir Alafenamide（TAF）(Fumate)（GS-7340） Tenofovir Alafenamide(TAF)(GS-7340) TENOFOVIR ALAFENAMIDE; GS7340; GS Tenofovir alafenamide fumage Tenofovir Alafenamide free base GS7340 (2S)-isopropyl 2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate isopropyl ((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate tenofovir alafenamide propan-2-yl (2S)-2-{[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propa n-2-yl]oxy}methyl)(phenoxy)phosphoryl]amino}pr opanoate Tenofovir Alafenamide (100mg/mL in Methanol) Tenofovir alafenamide semifumate Tenofovir Alafenamide //BP Tenofovir alafenamide Intermediate 2 Tenofovir Impurity 51 N-[[S(P)]-[2-(Adenin-9-yl)-1(R)-methylethoxymethyl](phenoxy)phosphoryl]-L-alanine isopropyl ester Tenofovir Alafenamide 25 mg tablets Tenofovir Alafenamide fumate, N-[[S(P)]-[2-(Adenin-9-yl)-1(R)-methylethoxymethyl](phenoxy)phosphoryl]-L-alanine isopropyl ester (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate GS-7340-03 GS-7340 Tenofovir alafenamide Sp-Tenofovir-phosphonamidate,phenyl,L-alanine isopropyl ester Tenofovir Alafenamide Base N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-L-alanine 1-methylethyl ester N-[[S(P)]-[2-(Adenin-9-yl)-1(R)-methylethoxymethyl](phenoxy) Tenofovir and alafenamide GS7340; GS-7340; GS 7340; TAF; TENOFOVIR ALAFENAMIDE; GENVOYA Tenofovir Alafenamide-d6 D6-Tenofovir Alafenamide(Mixture of Diastereomers) L-Alanine, N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy] methyl]phenoxyphosphinyl]-L-alanine 1-methylethyl phenyl hydrogen ((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate (2R,3S)-2,3-bis(4-chlorophenyl)butane-2,3-diamine |
| Description | Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. |
|---|---|
| Related Catalog | |
| Target |
HIV-1, NRTIs[1] |
| In Vitro | Tenofovir alafenamide antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC50 varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC50s range from 0.1 to 12 nM, with a mean EC50 of 3.5 nM compared to a mean EC50 of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC50s are 1.8 nM for TAF and 6.4 nM for AZT[2]. |
| In Vivo | Tenofovir alafenamide hemifumarate is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF)[1]. |
| References |
| Density | 1.39±0.1 g/cm3 |
|---|---|
| Boiling Point | 640.4±65.0 °C at 760 mmHg |
| Molecular Formula | C21H29N6O5P |
| Molecular Weight | 476.466 |
| Flash Point | 341.1±34.3 °C |
| Exact Mass | 476.193695 |
| PSA | 153.29000 |
| LogP | 2.20 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.630 |
| Water Solubility | Practically insoluble (0.04 g/L) (25 ºC) |
| Hazard Codes | Xi |
|---|
|
~%
379270-37-8 |
| Literature: Chapman; Kernan; Prisbe; Rohloff; Sparacino; Terhorst; Yu Nucleosides, Nucleotides and Nucleic Acids, 2001 , vol. 20, # 4-7 p. 621 - 628 |
|
~%
379270-37-8 |
| Literature: Chapman; Kernan; Prisbe; Rohloff; Sparacino; Terhorst; Yu Nucleosides, Nucleotides and Nucleic Acids, 2001 , vol. 20, # 4-7 p. 621 - 628 |
|
~%
379270-37-8 |
| Literature: Colby, Denise A.; Martins, Andrew Anthony; Roberts, Benjamin James; Scott, Robert William; Solomon, Nicole S. Patent: US2013/90473 A1, 2013 ; |
|
~%
379270-37-8 |
| Literature: Colby, Denise A.; Martins, Andrew Anthony; Roberts, Benjamin James; Scott, Robert William; Solomon, Nicole S. Patent: US2013/90473 A1, 2013 ; |
|
~%
379270-37-8 |
| Literature: Colby, Denise A.; Martins, Andrew Anthony; Roberts, Benjamin James; Scott, Robert William; Solomon, Nicole S. Patent: US2013/90473 A1, 2013 ; |
|
~%
379270-37-8 |
| Literature: Chapman; Kernan; Prisbe; Rohloff; Sparacino; Terhorst; Yu Nucleosides, Nucleotides and Nucleic Acids, 2001 , vol. 20, # 4-7 p. 621 - 628 |
| Precursor 6 | |
|---|---|
| DownStream 0 | |